Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder.
Level 4 - case-series / case-control
Uncontrolled observational study pooling data across two clinical cohorts
PubMed 30967101 · doi:10.1080/02791072.2019.1598603
What was done
Researchers evaluated the subjective and psychotropic experiences of 44 individuals undergoing ibogaine HCl treatment for opioid use disorder across two observational study sites (Mexico, n = 30; New Zealand, n = 14). Following treatment, participants completed the States of Consciousness Questionnaire (SCQ) to quantitatively measure the intensity of their subjective experience and provided written transcripts that were analyzed for qualitative thematic patterns.
What was found
Mean SCQ domain scores frequently exceeded 0.6, the established cutoff for a complete mystical experience, with 43% of participants meeting this threshold in more than five of the seven assessed domains. Qualitative thematic analysis revealed strong oneiric, visual, and auditory phenomena, cyclic visions prompting confrontation with past actions and remorse, resolution of guilt and worthlessness, and feelings of spiritual transformation.
Why it matters
This study documents that the psychological and oneiric experiences induced by ibogaine involve intense cognitive and emotional restructuring that may contribute to therapeutic outcomes independently of direct neurochemical effects on withdrawal and craving.
Limits
The study is limited by a small, combined sample size (n = 44) and an open-label, non-randomized observational design with no control or comparator group. The abstract does not report clinical retention rates, long-term abstinence outcomes, or objective safety and adverse event data.